Clinical trials: Tree Nut Allergy
Peanut Allergy
CNP-201 in Subjects With Peanut Allergy
This study is a Phase 1b/2a clinical trial to assess the safety, tolerability, and pharmacodynamics of multiple ascending doses (Escalation Phase) of CNP-201 with the goal of identifying a safe and tolerable dose level to be…
- Trial name
- NCT05250856
- Testing
- CNP-201
- Where
- 17 sites in United States
- Volunteers
- 15 people
- Sponsor
- COUR Pharmaceutical Development Company, Inc.
Peanut Allergy
Salvage Peanut Oral Immunotherapy Study
The purpose of this trial is to study the safety of rescue peanut oral immunotherapy followed by the introduction of dietary peanut for patients with peanut allergy who have lost desensitization during a peanut immunotherapy…
- Trial name
- SOIT (NCT03251508)
- Testing
- Peanut OIT
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of North Carolina, Chapel Hill
Food Allergy in Infants, Nut Allergy
The TreEat Study- Can Early Introduction of Tree Nuts Prevent Tree Nut Allergy in Infants With Peanut Allergy
Early and regular ingestion of the common allergens, peanut and egg has been shown to be an effective allergy prevention strategy. It is not clear whether this is also true of tree nut allergy.
- Trial name
- TreEat (NCT04801823)
- Testing
- Home introduction, Multi Nut oral food challenge
- Where
- Australia
- Volunteers
- 212 people
- Sponsor
- Murdoch Childrens Research Institute
Peanut Allergy
Peanut Oral Induction Tolerance in Peanut's Allergic Teenagers
The primary purpose of the protocol is to evaluate the efficacy of a protocol for induction of tolerance to peanut ingestion increasing doses. The secondary purpose is to determine the interest of a prolonged maintenance therapy
- Trial name
- PITA 3 (NCT02046083)
- Testing
- arachid
- Where
- France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Clermont-Ferrand
Food Hypersensitivity
Mechanisms of Desensitization During Peanut Oral Immunotherapy
The purpose of this study is to attempt to understand how desensitization works in peanut allergic children who are undergoing oral immunotherapy (OIT) to peanut.
- Trial name
- PnOIT4 (NCT01814241)
- Testing
- Open label peanut OIT
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of North Carolina, Chapel Hill
Peanut Allergy
Pinpoint Trial: Prebiotics IN Peanut Oral ImmunoTherapy
The purpose of this research is to gather information on the safety and efficacy of using a prebiotic as an adjunctive therapy to peanut oral immunotherapy.
- Trial name
- NCT05138757
- Testing
- Prebiotic
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of Chicago
Food Allergy, Food Allergy in Infants
Basophil Activation Test to Diagnose Food Allergy
The BAT II Study is a cross-sectional diagnostic study in which children with suspected IgE-mediated allergy to foods (namely cow's milk, egg, sesame and cashew), as defined by a history of an immediate-type allergic reaction to…
- Conditions
- Food Allergy, Food Allergy in Infants, Food Allergy in Children, Food Allergen Sensitisation
- Trial name
- BAT2 (NCT03309488)
- Testing
- Oral food challenge
- Where
- United Kingdom
- Volunteers
- 600 people
- Sponsor
- King's College London
Peanut Allergy
HAL-MPE1 Safety and Tolerability Study
The aim of this study is to confirm safety and tolerability of incremental doses of HAL-MPE1 subcutaneous immunotherapy (SCIT) in peanut allergic adults, and subsequently assess the safety and tolerability in adolescents and…
- Trial name
- NCT02991885
- Testing
- HAL-MPE1
- Where
- 7 sites in United States, Canada
- Volunteers
- 42 people
- Sponsor
- HAL Allergy
Peanut Allergy
Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-201 in Subjects Ages 16-35 With Peanut Allergy
This study is a two-part Phase 1b/2a First-in-Human (FIH) randomized, double-blind, placebo-controlled clinical trial to assess the safety, tolerability, pharmacodynamics, and efficacy of multiple ascending doses of CNP-201 in…
- Trial name
- NCT04950504
- Testing
- CNP-201
- Where
- 9 sites in United States
- Volunteers
- 9 people
- Sponsor
- COUR Pharmaceutical Development Company, Inc.
Peanut Allergy
Validation of the HYPONUT Product
The HYPONUT product was previously validated in a laboratory setting ("Procédé de préparation d'aliment hypoallergénique", n° FR1250977) on 2012. A international patent was then obtained on 2013.
- Trial name
- NCT03849079
- Testing
- Hyponut
- Where
- France
- Volunteers
- 6 people
- Sponsor
- University Hospital, Montpellier
Food Allergy
Long-term Extension Study of Ligelizumab in Food Allergy
This was an extension study to evaluate the long-term safety and efficacy of ligelizumab in participants who completed a ligelizumab Phase III study in food allergy.
- Trial name
- NCT05678959
- Testing
- Ligelizumab 120 mg, Ligelizumab 240 mg
- Where
- 49 sites in United States, Australia and 7 more
- Volunteers
- 163 people
- Sponsor
- Novartis Pharmaceuticals
Peanut Allergy
Reactive Doses and Times During Oral Food Challenge to Peanut
Peanut allergy is a growing public health problem in developed countries with more and more hospitalizations for anaphylaxis. It has been determined that sensitization to certain peanut proteins such as rAra h 2, is predictive of…
- Trial name
- PeaNewT (NCT03852342)
- Where
- France
- Volunteers
- 262 people
- Sponsor
- University Hospital, Montpellier
Peanut Allergy, Food Allergy in Children
A Randomized, Controlled Trial of Probiotic and Peanut Oral Immunotherapy (PPOIT) in Inducing Tolerance in Hong Kong Children With Peanut Allergy Compared With Oral Immunotherapy (OIT) Alone and With Placebo
At present there is no cure for food allergy. People with a food allergy need to avoid the food they are allergic to in order to stay safe. However we know that accidental exposure is common.
- Trial name
- NCT05165329
- Testing
- PEANUT OIT: Peanut Flour (50% peanut protein) that is prepared under food manufacturing regulations
- Where
- 4 sites in Hong Kong
- Volunteers
- 90 people
- Sponsor
- Chinese University of Hong Kong
Tree Nut Allergy
Walnut Oral Immunotherapy for Tree Nut Allergy
The purpose of this study is to determine if walnut oral immunotherapy can be used in participants allergic to tree nuts to reduce tree nut allergy and induce changes in the participant's immune system.
- Trial name
- WOIT (NCT01546753)
- Testing
- Walnut Protein Powder, Open-label Walnut Protein Powder
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Arkansas
Peanut Allergy
Expanded Access Protocol of Viaskin® Peanut (DBV712) in Peanut-allergic Children
This is an open label expanded access program for male and female patients 2 years or older, to provide continued desensitization treatment with DBV712 250 mcg.
- Trial name
- NCT05424731
- Testing
- DBV712 250 mcg
- Where
- United States
- Sponsor
- DBV Technologies
Food Hypersensitivity
Take Away Food Allergy; Inducing Tolerance in Children Allergic to Peanut
The purpose of the study is to identify prognostic markers and possible success rate of tolerance induction to peanut allergens in children allergic to peanut.
- Trial name
- NCT02457416
- Testing
- Peanut
- Where
- Norway
- Volunteers
- 77 people
- Sponsor
- Oslo University Hospital
Peanut Allergy
Safety of MOON101 for the Treatment of Peanut Allergy
The goal of this open-label, single escalating dose study in 3 sequential groups: adults, adolescents, and children with peanut allergy is to assess the safety of MOON101. The main question it aims to answer is: 1.
- Trial name
- SURVEYOR (NCT07580898)
- Testing
- Dose A, Dose B, Dose C
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- Moonlight Therapeutics, Inc.
Allergy, Peanut
Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age
The primary purpose of this study is to assess the efficacy and safety of daily DBV712 250 micrograms (mcg) to induce desensitization to peanut in peanut-allergic children 4-7 years of age over a 12-month double-blind…
- Trial name
- VITESSE (NCT05741476)
- Testing
- DBV712
- Where
- 87 sites in United States, Australia and 7 more
- Volunteers
- 600 people
- Sponsor
- DBV Technologies
Peanut Allergy
Adjuvant Treatment With Abatacept to Promote Remission During Peanut Oral Immunotherapy
This is a phase 2a, multi-center, randomized and double-blind placebo-controlled trial comparing 24 weeks of abatacept versus placebo used as adjuvant to oral immunotherapy to induce remission in adolescents and adults with…
- Trial name
- ATARI (NCT04872218)
- Testing
- Abatacept, Peanut oral immunotherapy
- Where
- Canada
- Volunteers
- 14 people
- Sponsor
- Philippe Bégin
Peanut Allergy, Tree Nut Allergy
Peanut and Tree Nut Desensitization
this study evaluates whether tolerance to peanuts and tree nuts can be induced in patients through a process of oral immunotherapy.
- Trial name
- NCT03532360
- Testing
- Oral immunotherapy
- Where
- 2 sites in Canada
- Volunteers
- 51 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre